Pityriasis Versicolor Resistant to Antifungal Drugs in a Patient in Lomé (Togo).

Autor: Teclessou J; Department of, Dermatology and STDs, University Teaching Hospital of Campus, Togo., Kombate K; Department of, Dermatology and STDs, University Teaching Hospital of Campus, Togo., Saka B; Department of Dermatology and STDs, University Teaching Hospital of Sylvanus Olympio, Togo., Akakpo SA; Department of Dermatology and STDs, University Teaching Hospital of Sylvanus Olympio, Togo., Pitche P; Department of Dermatology and STDs, University Teaching Hospital of Sylvanus Olympio, Togo.
Jazyk: angličtina
Zdroj: Case reports in dermatological medicine [Case Rep Dermatol Med] 2022 Aug 22; Vol. 2022, pp. 5404913. Date of Electronic Publication: 2022 Aug 22 (Print Publication: 2022).
DOI: 10.1155/2022/5404913
Abstrakt: Background: Pityriasis versicolor (PV) is a ubiquitous superficial skin mycosis that often affects young adults. It is often effectively treated with local or oral antifungal agents. Cases of PV resistance to antifungal agents have been reported rarely. We report a case of antifungal resistant PV. Observation . A 22-year-old patient was followed since the age of 17 years in a dermatology outpatient clinic for hyperpigmented scaly macular lesions of the trunk and upper limbs. The clinical diagnosis of PV was retained. The patient was treated by fluconazole 300 mg/week before being lost to follow-up. He was seen again in 2019 (about 2 years later) for the same symptomatology and treated again by fluconazole and ciclopirox olamine cream without improvement. He was again lost to follow-up and seen again six months later. A mycological sample was taken and Aspergillus niger was isolated. The patient was treated by itraconazole for 6 weeks. The evolution was marked by a clinical status quo. The patient was again put on salicylated petroleum jelly 10% associated with terbinafine cream and then lost to follow-up.
Conclusion: The emergence of fungal resistance to antifungal drugs does not spare PV. It can therefore be resistant to several antifungal drugs, leaving clinicians and patients in despair.
Competing Interests: The authors declare that they have no conflicts of interest.
(Copyright © 2022 Julienne Teclessou et al.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje